Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Hematology Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark.
Blood Adv. 2022 Apr 26;6(8):2701-2706. doi: 10.1182/bloodadvances.2021005716.
The chronic lymphocytic leukemia comorbidity index (CLL-CI) is an efficient, CLL-specific tool derived from the Cumulative Illness Rating Scale. The CLL-CI is based on the assessment of the organ systems found to be most strongly associated with event-free survival (EFS) in CLL: vascular, upper gastrointestinal, and endocrine, at the time of initiation of CLL therapy. The CLL-CI categorizes patients into low, intermediate, and high risk groups. In the present study, we have employed the CLL-CI in a population-based cohort comprising 4975 patients with CLL. We demonstrate that CLL-CI retains prognostic significance in this large cohort and is associated with overall survival (OS) and EFS from time of first therapy. Furthermore, CLL-CI associates with OS, EFS, and time to first treatment from diagnosis independently of the CLL International Prognostic Index. These findings support the use of the CLL-CI both in research and in clinical practice.
慢性淋巴细胞白血病合并症指数（CLL-CI）是一种源自累积疾病评分量表的高效、特定于 CLL 的工具。CLL-CI 基于对与 CLL 无事件生存（EFS）最密切相关的器官系统的评估：血管、上胃肠道和内分泌，在开始 CLL 治疗时。CLL-CI 将患者分为低、中、高危组。在本研究中，我们在一个包含 4975 例 CLL 患者的基于人群的队列中使用了 CLL-CI。我们证明 CLL-CI 在这个大队列中保留了预后意义，并且与首次治疗时的总生存（OS）和 EFS 相关。此外，CLL-CI 与 OS、EFS 和从诊断到首次治疗的时间相关，独立于 CLL 国际预后指数。这些发现支持 CLL-CI 在研究和临床实践中的应用。
Zotero 插件